Literature DB >> 2836573

Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer.

M Nakajo1, H Kobayashi, K Shimabukuro, K Shirono, H Sakata, M Taguchi, N Uchiyama, T Sonoda, S Shinohara.   

Abstract

The biodistribution and in vivo kinetics of [131I]lipiodol infused into the hepatic artery were studied to estimate the potential of internal radiotherapy of hepatic cancer in five patients. It accumulated only in the vascular tumors and adjacent hepatic tissue (AHT) supplied by the infused artery, and to a lesser extent in the lung throughout 8 days imaging sequence. Iodine-131 lipiodol appeared to lead to oil embolization of the tumor and AHT followed by secondary embolization to the lungs and finally the activity was mainly excreted into urine. Four tumors had rapidly and slowly decreasing components, while the AHT activity decreased exponentially from the beginning. The effective half life in tumors was longer with the slow component (mean +/- s.d.: 5.7 +/- 1.2 days) than the AHT (3.7 +/- 0.6 days). The tumor/AHT concentration ratio in three patients at 2 hr was estimated to be 7.5-21. The activity was lower in the lungs than in the AHT in four patients. Iodine-131 lipiodol thus may be used as an intra-arterial infusion agent to treat certain vascular hepatic cancers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836573

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  Ablation of recurrent primary liver cancer using 131I-lipiodol.

Authors:  R Novell; A Hilson; K Hobbs
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

2.  Application of radiobiological dosimetry to radionuclide directed therapy.

Authors:  W T Millar
Journal:  Br J Cancer Suppl       Date:  1990-07

3.  (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.

Authors:  Bieke Lambert; Klaus Bacher; Luc Defreyne; Hans Van Vlierberghe; Jae Min Jeong; Rong Fu Wang; Jan van Meerbeeck; Peter Smeets; Roberto Troisi; Hubert Thierens; Filip De Vos; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12-07       Impact factor: 9.236

4.  Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG.

Authors:  Y Nakabeppu; M Nakajo
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

5.  Transarterial internal radiation therapy with I-131 Lipiodol for multifocal hepatocellular carcinoma: immediate and long-term results.

Authors:  Y Kajiya; H Kobayashi; M Nakajo
Journal:  Cardiovasc Intervent Radiol       Date:  1993 May-Jun       Impact factor: 2.740

6.  Patient dosimetry for 131I-lipiodol therapy.

Authors:  Myriam A Monsieurs; Klaus Bacher; Boudewijn Brans; Anne Vral; Leo De Ridder; Rudi A Dierckx; Hubert M Thierens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-01       Impact factor: 9.236

7.  Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution.

Authors:  Y Yumoto; K Jinno; S Inatsuki; S Moriwaki; T Hanafusa; E Yumoto; T Shiota; T Higashi; N Koide; H Hada
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 8.  Clinical pharmacokinetic advantages of new drug delivery methods for the treatment of liver tumours.

Authors:  J H Anderson; H W Warren; C S McArdle
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

9.  Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol.

Authors:  H S Yoo; C H Park; J T Lee; K W Kim; C S Yoon; J H Suh; C Y Park; B S Kim; H J Choi; K S Lee
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Intra-arterial infusion of N-isopropyl-p[123I]iodoamphetamine for assessing effective blood supply to pulmonary and hepatic neoplasms.

Authors:  C Miyazaki
Journal:  Ann Nucl Med       Date:  1994-05       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.